Regression of left ventricular hypertrophy with SGLT2 inhibitors

Francesco Paneni^{1

2

3}, Sarah Costantino¹, Nazha Hamdani^{4

5

6}

Affiliations

¹ Center for Molecular Cardiology, University of Zürich, Switzerland.
² University Heart Center, Cardiology, University Hospital Zurich, Switzerland.
³ Department of Research and Education, University Hospital Zurich, Switzerland.
⁴ Institute of Physiology, Ruhr University, Bochum, Germany.
⁵ Molecular and Experimental Cardiology, Ruhr University, Bochum, Germany.
⁶ Department of Cardiology, St-Josef Hospital, Ruhr University, Bochum, Germany.

Comment

Francesco Paneni et al. Eur Heart J. 2020.

. 2020 Sep 21;41(36):3433-3436.

doi: 10.1093/eurheartj/ehaa530.

Francesco Paneni^{1

2

3}, Sarah Costantino¹, Nazha Hamdani^{4

5

6}

¹ Center for Molecular Cardiology, University of Zürich, Switzerland.
² University Heart Center, Cardiology, University Hospital Zurich, Switzerland.
³ Department of Research and Education, University Hospital Zurich, Switzerland.
⁴ Institute of Physiology, Ruhr University, Bochum, Germany.
⁵ Molecular and Experimental Cardiology, Ruhr University, Bochum, Germany.
⁶ Department of Cardiology, St-Josef Hospital, Ruhr University, Bochum, Germany.

No abstract available

Comment on

A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial.
Brown AJM, Gandy S, McCrimmon R, Houston JG, Struthers AD, Lang CC. Brown AJM, et al. Eur Heart J. 2020 Sep 21;41(36):3421-3432. doi: 10.1093/eurheartj/ehaa419. Eur Heart J. 2020. PMID: 32578850 Free PMC article. Clinical Trial.